Onco-Innovations initiates ADME studies for lead cancer drug candidate ONC010

• Onco-Innovations initiated ADME studies for ONC010, its lead nanoparticle-formulated PNKP inhibitor, to support IND-enabling development.
• Work targets metabolism of the active pharmaceutical ingredient to inform manufacturing decisions, formulation optimization, toxicology planning.
• Program aims to build pharmacokinetic and metabolic data to support dose selection, safety assessment, future clinical evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202607161800TNWSWRCACNPR_____1knDF1lX4) on July 16, 2026, and is solely responsible for the information contained therein.